Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Hangzhou Dac Biotech Co. Ltd. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 3 pending office actions. This indicates a level of active prosecution across the company's biotechnological filings. These 3 pending office actions represent the current administrative workload for the company's intellectual property assets at the USPTO.
The workload is distributed among 3 distinct examiners and 2 distinct art units. This suggests that the company's innovations are being evaluated across different technical specialties within the USPTO, though some overlap exists within the 2 distinct art units. VAN DRUFF, SYDNEY is identified as the busiest examiner for this portfolio. The involvement of 3 distinct examiners requires a strategy that accounts for multiple individual perspectives.
VAN DRUFF, SYDNEY is responsible for 1 busiest examiner pending office action. Since there are 3 pending office actions in total, the company's prosecution strategy is split between multiple individuals. Practitioners should manage these parallel tracks by considering the specific requirements of each examiner and the 2 distinct art units involved. The 1 busiest examiner pending office action is one component of the broader docket.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18156748 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | VAN DRUFF, SYDNEY | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17426813 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | CANELLA, KAREN A | 15d overdue |
| 18156748 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | VAN DRUFF, SYDNEY | 16d |
| 17256034 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | BRAUN, MADELINE E | 19d |
| 17389922 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1626 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18156748 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | VAN DRUFF, SYDNEY | 1643 | §102§103§112 | Non-Final OA | 16d | Pending | Jan 19, 2023 |
| 17389922 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | COUGHLIN, MATTHEW P | 1626 | §112 | Non-Final OA | — | Pending | Jul 30, 2021 |
| 17426813 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | CANELLA, KAREN A | 1643 | §112 | Final Rejection | 15d overdue | Pending | Jul 29, 2021 |
| 17256034 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | 19d | Pending | Dec 24, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Dac Biotech Co. Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Sydney Van Druff has the most, with 1 of Hangzhou Dac Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
